NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria (SIS – Research Report) today and set a price target of ...

NVG-291 is under clinical development by NervGen Pharma and currently in Phase II for Spinal Cord Injury. According to GlobalData, Phase II drugs for Spinal Cord Injury does not have sufficient ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated t... "Lorem ipsum dolor sit amet, ...

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...

Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024Protocol being amended to enhance enrollment and lessen burden on participants in t... "Lorem ipsum dolor sit amet, ...

We announced to the SCI community that we will cover the cost of travel and accommodation for participants during the 16-week trial," said Mike Kelly, NervGen's President & CEO. "These initiatives are ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.